Application of Artificial Intelligence Techniques for Non-Alcoholic Fatty Liver Disease Diagnosis: A Systematic Review (2005–2023) Publisher Pubmed



Zamanian H¹ ; Shalbaf A¹ ; Zali MR² ; Khalaj AR³ ; Dehghan P⁴ ; Tabesh M⁵ ; Hatami B² ; Alizadehsani R⁶ ; Tan RS^{7, 8} ; Acharya UR^{9, 10}
Source: Computer Methods and Programs in Biomedicine Published:2024

Abstract

Background and objectives: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease with a rapidly growing incidence worldwide. For prognostication and therapeutic decisions, it is important to distinguish the pathological stages of NAFLD: steatosis, steatohepatitis, and liver fibrosis, which are definitively diagnosed on invasive biopsy. Non-invasive ultrasound (US) imaging, including US elastography technique, and clinical parameters can be used to diagnose and grade NAFLD and its complications. Artificial intelligence (AI) is increasingly being harnessed for developing NAFLD diagnostic models based on clinical, biomarker, or imaging data. In this work, we systemically reviewed the literature for AI-enabled NAFLD diagnostic models based on US (including elastography) and clinical (including serological) data. Methods: We performed a comprehensive search on Google Scholar, Scopus, and PubMed search engines for articles published between January 2005 and June 2023 related to AI models for NAFLD diagnosis based on US and/or clinical parameters using the following search terms: “non-alcoholic fatty liver disease”, “non-alcoholic steatohepatitis”, “deep learning”, “machine learning”, “artificial intelligence”, “ultrasound imaging”, “sonography”, “clinical information”. Results: We reviewed 64 published models that used either US (including elastography) or clinical data input to detect the presence of NAFLD, non-alcoholic steatohepatitis, and/or fibrosis, and in some cases, the severity of steatosis, inflammation, and/or fibrosis as well. The performances of the published models were summarized, and stratified by data input and algorithms used, which could be broadly divided into machine and deep learning approaches. Conclusion: AI models based on US imaging and clinical data can reliably detect NAFLD and its complications, thereby reducing diagnostic costs and the need for invasive liver biopsy. The models offer advantages of efficiency, accuracy, and accessibility, and serve as virtual assistants for specialists to accelerate disease diagnosis and reduce treatment costs for patients and healthcare systems. © 2023